New RSV vaccine LYB005 enters human trials for seniors
NCT ID NCT07208461
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new vaccine called LYB005 against RSV, a virus that can cause serious lung infections in older adults. About 700 volunteers aged 60 and older will receive either the vaccine or a placebo. Researchers will check how well the vaccine boosts the immune system and whether it is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LYB005 RSV vaccine (with or without A01B adjuvant)
- What this could lead to
- If successful, this could lead to a safe and effective RSV vaccine for older adults, reducing severe respiratory infections.
- What could go wrong
- This is an early Phase 2 trial, so results may not confirm effectiveness. The vaccine might not produce strong enough immunity or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION PREVENTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Disease Control and Prevention of Dangyang City
Dangyang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.